Press "Enter" to skip to content

News

Glu Mobile stock soars to 11-year high

Glu Mobile Inc. (GLUU) stock soared to over 11-year high to reach $11.46 on Tuesday. Investors were cautious after the mobile game publisher reported disappointing results for the fourth quarter but believed the stock to be a good investment. This was based on the future of mobile games and the pace at which the industry is improving.

Majority of the analysts recommended a “strong buy” or “buy” rating with an average price target of $10.54. With the stock reaching the second peak, traders expect the sell-side analysts to revise their price target in the coming days. The analysts tend to value the company much more than the current scenario.

They believed that Glu Mobile developing the next generation Deer Hunter franchise could provide a huge potential in the next year as the mobile shooter game is currently slated to be released in beta in late 2019. The game looks to build upon the success of previous Deer Hunter titles which have generated more than a quarter billion downloads since Glu acquired the IP in 2012.

Glu Mobile Deer Hunter 2018 game
Image Courtesy: Glu Mobile

According to market researcher Newzoo, the global gaming market is set to exceed $180 billion in revenues in 2021, up by 30.6% from $137.9 billion in 2018. This was due to an increase in the number of people playing games as Newzoo estimates that to be about 2.3 billion. The mobile games, which could contribute more than half of the game revenues, are anticipated to grow from $70.3 billion this year to $106.4 billion by 2021.

Over the past year, the company’s new games roadmap has worsened due to the delay or cancel of multiple titles. Traders remained concerned about the current scenario but could turn positive if the future game’s roadmap becomes more clear and the beta lineup started increasing.

For the fourth quarter, Glu Mobile reported a narrower loss as a strong performance from Growth Games drove bookings higher by 18%. Revenue increased by 19% year-over-year. The results were benefited by the successful execution of its live operations strategy through enhanced gaming experience, improved merchandising and strategic advertising placement.

The company had expected bookings in the range of $88 million to $90 million for the first quarter of 2019 and in the range of $435 million to $445 million for the year 2019. The company has three new launches that are all in various stages of development with a plan to go live in the May to August 2019 timeframe. The company has three additional games in various stages of development for the 2020 timeframe.

Shares of Glu Mobile opened higher on Tuesday and is trading in the green territory. The stock has risen over 207% in the past year and over 60% in the past three months.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results

After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during the pre-market trading on positive top-line results from its eye inflammation disease trial. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of the eye drug reproxalap.

The company announced positive results from its Phase 3 ALLEVIATE Trial of reproxalap, its eye drug, in patients with allergic conjunctivitis.

In preparation for subsequent clinical testing, Aldeyra is conducting clinical method development studies to assess the feasibility of measuring ocular itching induced by environmental exposure to allergen.

Also read: Aldeyra Therapeutics (ALDX) Q4 2018 Earnings Conference Call Transcript

In the second half of 2019, Aldeyra plans to meet with regulatory authorities to discuss the ALLEVIATE results and remaining clinical requirements for a potential submission of a New Drug Application to the FDA.

CEO Todd Brady said, “Consistent with positive results from five prior Phase 2 clinical trials in ocular inflammation, today’s announcement confirms the potential of reproxalap as a novel and clinically meaningful approach for the treatment of allergic conjunctivitis. Given that approximately half of allergic conjunctivitis patients also suffer from ocular dryness, we believe the ALLEVIATE results highlight the relevance of reproxalap to our current Phase 3 program in dry eye disease.”

The company also announced that it entered into a $60 million loan and security agreement with Hercules Capital.

Aldeyra stock had declined 14% since the beginning of this year and 11% in the past 12 months.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

 

Featured Articles

Products

Calendar

Be the first to know If the company will miss, meet or beat its target with the most accurate corporate and earnings

On Demand Audios

Missed the call, don’t worry! Check out our archived audio library to hear what the management said and the analyst asked.

Transcripts

Catch the nuances in the call, research what the management and analysts feel about the future? Read it all here!

SEC Docs

Get 8-K, 10-K, 10-Q SEC filings for the companies you research with keyword search or our filtering options.

Products

Calendar

Be the first to know If the company will miss, meet or beat its target with the most accurate corporate and earnings calendar.

On Demand Audios

Missed the call, don’t worry! Check out our archived audio library to hear what the management said and the analyst asked.

Transcripts

Catch the nuances in the call, research what the management and analysts feel about the future? Read it all here!

SEC Docs

Get 8-K, 10-K, 10-Q SEC filings for the companies you research with keyword search or our filtering options.

Top